Life Sciences: Biotech
FDA warning drives doubts on Epogen drug
A Food and Drug Administration warning about the use of antianemia drugs is increasing pressure on Medicare officials to change payment policies for Amgen Inc.'s Epogen, which accounts for $2 billion in federal kidney-dialysis reimbursements. (Full article: 951 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $9.95 1 month archives pass
- $24.95 3 months archives pass
- $74.95 1 year archives pass
